Antithymocyte globulin - Fresenius Biotech

Drug Profile

Antithymocyte globulin - Fresenius Biotech

Alternative Names: Anti-T-lymphocyte immune globulin; Antithymocyte immunoglobulin (rabbit) - Fresenius; ATG S Fresenius; ATG-Fresenius-S; ENZN-2053; EZ-2053; Grafalon; US-ATG-F

Latest Information Update: 12 Oct 2016

Price : $50

At a glance

  • Originator Fresenius Biotech
  • Developer Neovii Biotech
  • Class Polyclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Graft-versus-host disease; Renal transplant rejection; Transplant rejection
  • Discontinued Lung transplant rejection

Most Recent Events

  • 06 Oct 2016 Antithymocyte globulin licensed to Zydus-Cadila in India
  • 15 Jan 2016 Efficacy data from a phase III trial in Graft-versus-host disease released by Neovii
  • 28 Sep 2015 Launched for Graft-versus-host disease (Prevention) in Netherlands (IV) before September 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top